News: Webinar: Immunoregulation and the tumor microenvironment

February 2, 2021 | Webinar: Immunoregulation and the tumor microenvironment | IUIS

Join the next IUIS (International Union of Immunological Societies), Immunopaedia and Frontiers webinar on immunoregulation and the tumor microenvironment with Pamela Ohashi. Supported by Thermo Fisher Scientific – LIVE on February 8, 16:00 SAST


Although PD-1 blockade has transformed cancer treatment, a deeper understanding of tumor immunobiology and inhibitory mechanisms are needed to take immunotherapy to the next level. My talk will cover topics including the cell types that express key B7 family members and their receptors including PD-L1, B7-H3, B7-H4 and PD-1 and discuss whether these findings align with the traditional views for what is going on in the tumor microenvironment. In addition, I will cover unexpected immunoregulatory mechanisms that we have found focusing on innate lymphoid cells.


Monday February 8, 2021, starting at 3:00 PM CET


Dr. Ohashi received her Ph.D from the University of Toronto with Dr. Tak Mak, and did her post-doctoral training at the University of Zurich with the Nobel Laureate Dr. Zinkernagel, and Dr. Hans Hengartner. She is a Senior Scientist and Director of the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre, and a Professor in the Department of Immunology at the University of Toronto. Her interests include understanding CD8+ T cell biology and mechanisms that regulate anti-tumor immunity.

This webinar is supported by: Thermo Fisher Scientific

Thermo Fisher Scientific understands your samples are precious in immunology research. Our products and technologies support your wise use of samples to get qualitative and quantitative measurements when evaluating experiments. Our mission is to enable our customers to make the world healthier, cleaner, and safer.

The production of this webinar is supported by Thermo Fisher Scientific. Thermo Fisher Scientific has had no influence on the content, and full editorial control remains the sole responsibility of IUIS